Company news

Share this article:
Amylin has announced a corporate restructuring that will result in a reduction of workforces by 25%, or 340 employees. “Sales revenues have not met the expectations we had when we scaled up our organization,” said Daniel Bradbury, president and CEO at Amylin, in a statement.
 
A Pfizer manufacturing plant in Indiana has been put up for sale. The plant most recently manufactured Exubera, an inhaled insulin therapy, which didn't catch on with patients.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.